SCHEMBL4170396

SCHEMBL4170396

CCOC(=N)c1ccc2[nH]nc(-c3ccc4cc(OCCc5cccnc5)ccc4c3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.42
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
TTK P33981 5/20 0.42
MAPK8 P45983 4/20 0.42
FGFR1 P11362 1/20 0.39
WNT1 P04628 2/20 0.39
FGFR4 P22455 1/20 0.39
HRH4 Q9H3N8 1/20 0.39
MAP2K4 P45985 1/20 0.39
CLK2 P49760 1/20 0.38
CLK3 P49761 1/20 0.38
DYRK1A Q13627 1/20 0.38
MAPK1 P28482 1/20 0.38
CHEK1 O14757 1/20 0.37
PLAU P00749 1/20 0.37
MAOB P27338 1/20 0.37
MMP2 P08253 1/20 0.36
MMP13 P45452 1/20 0.36
MMP14 P50281 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4083137 0.91 FGFR1 (0.47) CYP19A1CYP11B1CYP11B2TTKMAPK8
SCHEMBL4089678 0.84 TTK (0.45) TTKMAPK8FGFR1FGFR4MAPK1
SCHEMBL4079832 0.82 TTK (0.43) TTKMAPK8MAP2K4MAPK1
SCHEMBL4089601 0.82 BRAF (0.44) TTKMAPK8WNT1
SCHEMBL4043448 0.80 BTK (0.45) TTKMAPK8MAP2K4MAPK1
SCHEMBL4084769 0.80 TTK (0.48) TTKMAPK8MAP2K4MAPK1
Hydrochloric Acid SCHEMBL5397824 0.79 BTK (0.44) TTKMAPK8MAP2K4MAPK1
Hydrochloric Acid SCHEMBL4083323 0.79 BTK (0.44) TTKMAPK8MAP2K4MAPK1
SCHEMBL4090303 0.79 TBXAS1 (0.48) CYP19A1
SCHEMBL4083120 0.79 TTK (0.41) TTKMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 CYP19A1 2082/4885CYP11B1 202/4885CYP11B2 239/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 CYP19A1 2204/4885CYP11B1 220/4885CYP11B2 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.